The Comeback Begins? Positive Signs Seen For Humira Biosimilars In US
Sandoz Gets Adalimumab Bump And Teva/Alvotech Strike Deal, As Market Share Doubles In Q1
• By David Wallace
Humira biosimilars are bouncing back after initial slow uptake • Source: Shutterstock 
